Answers are grounded in this paper and cite their sources.
Whole-exome sequencing (WES) enables identification of medically actionable hereditary cancer predisposition findings beyond the primary diagnostic indication. We performed a retrospective analysis of 5100 clinical WES tests. After exclusion of 30 oncology-related cases, a non-oncological cohort of 5070 WES tests was used to evaluate pathogenic and likely pathogenic findings in hereditary breast and/or ovarian cancer predisposition genes. A variant-level dataset comprised 151 unique pathogenic or likely pathogenic variants. The overall detection frequency of pathogenic or likely pathogenic findings in hereditary breast and/or ovarian cancer predisposition genes was 7.1%. The highest gene-level frequencies were observed for CHEK2 (1.54%), ATM (1.34%), BRCA2 (0.75%), BRCA1 (0.61%) and PALB2 (0.59%). Moderate-penetrance hereditary cancer genes accounted for 3.81% of the cohort, slightly exceeding the frequency observed for high-penetrance hereditary cancer and Lynch syndrome-associated genes (3.33%). Among genes included in the ACMG secondary findings framework, BRCA2, BRCA1 , and mismatch repair genes accounted for most secondary findings, whereas PTEN and NF1 findings were predominantly phenotype-driven. Of the pathogenic and likely pathogenic findings, 46.7% occurred in genes included in the ACMG Secondary Findings framework, whereas 53.3% occurred in other hereditary cancer predisposition genes analysed in this study. This distribution reflects the deliberately selective scope of the ACMG SF framework and the broader spectrum of hereditary cancer susceptibility findings that may be encountered in clinical WES.
No takes yet. Share an insight, caveat, or question.
Czukiewska et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: